(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 January 2013 (10.01.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/004842 A3

(51) **International Patent Classification**:
A61K 39/395 (2006.01) ***C07K 16/28*** (2006.01)
A61P 35/00 (2006.01) ***C07K 16/36*** (2006.01)
C07K 16/00 (2006.01)

(21) **International Application Number**:
PCT/EP2012/063339

(22) **International Filing Date**:
6 July 2012 (06.07.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/504,994	6 July 2011 (06.07.2011)	US
PA 2011 00519	6 July 2011 (06.07.2011)	DK
PA 2012 00371	30 May 2012 (30.05.2012)	DK

(71) **Applicant** *(for all designated States except US)*: **GENMAB A/S** [DK/DK]; Bredgade 34 E, DK-1260 Copenhagen K (DK).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **PARREN, Paul** [NL/NL]; c/o Genmab B.V., Yalelaan 60, NL-3584 CM Utrecht (NL). **BEURSKENS, Frank** [NL/NL]; c/o Genmab B.V., Yalelaan 60, NL-3584 CM Utrecht (NL). **DE JONG, Rob N.** [NL/NL]; c/o Genmab B.V., Yalelaan 60, NL-3584 CM Utrecht (NL). **LABRIJN, Aran Frank** [NL/NL]; c/o Genmab B.V., Yalelaan 60, NL-3584 CM Utrecht (NL). **SCHUURMAN, Janine** [NL/NL]; c/o Genmab B.V., Yalelaan 60, NL-3584 CM Utrecht (NL).

(74) **Common Representative**: **GENMAB A/S**; Bredgade 34 E, DK-1260 Copenhagen K (DK).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
4 April 2013

WO 2013/004842 A3

(54) **Title**: ANTIBODY VARIANTS AND USES THEREOF

(57) **Abstract**: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC- response.